Watch GRI. Know when insiders buy.
One email the day a filing lands. Free.
GRI
GRI Bio, Inc.
1.81
−0.01 −0.55%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
70
PASS · shorts 70
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$9.7MNET CASH —52W 1.38 – 63.28SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.6M | −$1.6M | — | -0.91 | −$1.4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$2M | −$2M | — | -1.61 | −$3.7M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.7M | −$2.7M | — | -116.61 | −$3M | — | — | Jan 30 |
| Q3 2025 · Sep 30 | — | — | — | −$3.4M | −$3.4M | — | -1.28 | −$2.3M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$2.9M | −$2.9M | — | -36.72 | −$3.2M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3.1M | −$3M | — | -162.30 | −$1.7M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$2M | −$1.9M | — | -1468.00 | −$2M | $0 | −$2M | Jan 30 |
| Q3 2024 · Sep 30 | — | — | — | −$2.1M | −$2.1M | — | -11.42 | −$2.3M | $0 | −$2.3M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$2.3M | −$2.3M | — | -61.85 | −$2.1M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -101.05 | −$2.2M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$2M | −$2M | — | -4568.75 | −$5.6M | $0 | −$5.6M | Mar 14 |
| Q3 2023 · Sep 30 | — | — | — | −$2.4M | −$2.1M | — | -65.78 | −$1.3M | $0 | −$1.3M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$12M | −$12M | — | -121.80 | −$10.2M | $3K | −$10.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$8.2M | −$8.2M | — | -1545.55 | −$8.6M | $0 | −$8.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$11.4M | −$13M | — | -5018.09 | −$9M | $8K | −$9M | — | — |
| FY2022 · to Dec 31 | — | — | −$2.2M | −$3.2M | — | -24.95 | −$1.1M | $3K | −$1.1M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$9.3M | −$9.3M | — | -1.42 | −$8.3M | $0 | −$8.3M | — | — |
| FY2020 · to Dec 31 | $100K | — | −$4.8M | −$4.8M | -4822.0% | -1.07 | −$3.7M | $2K | −$3.7M | — | — |
Every number comes from GRI Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.